Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality

Jae-Ho Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee and Seok Lee

Abstract

Background: Cord blood transplantation (CBT) has been reported as an acceptable option with comparable outcomes to conventional donors in adults with acute lymphoblastic leukemia (ALL). We aimed to analyze the long-term CBT outcomes and risk factors for early and long-term mortalities.

Methods: Between 2006 and 2020, 112 patients (median age: 35 years; 62 Ph-negative ALL and 50 Ph-positive ALL) were treated with double CBT. Conditioning regimen consisted of total body irradiation (12 Gy) plus cytarabine (9.0 g/m²) plus fludarabine (150 mg/m²), and graft-versus-host disease (GVHD) prophylaxis was attempted by administering tacrolimus plus mycophenolate mofetil.

Results: The median time for neutrophil and platelet recovery was 25 days (range: 5–59 days) and 34 days (range: 7–185 days), respectively. The cumulative incidence of acute GVHD at 1 year was 43.8%, and the incidence of acute GVHD with grades III–IV was 8.9%. The overall cumulative incidence of chronic GVHD was 22.0%, and the incidence of moderate to severe chronic GVHD was 8.5%. After a median follow-up of 60.1 months (range: 5.7–181.3 months), the 5-year cumulative incidence of relapse (CIR) and nonrelapse mortality (NRM) were 15.9% and 28.5% (9.7% and 27.2% for CR1), respectively, and the 5-year overall survival (OS) was 57.9% (66.5% for CR1). In multivariate analysis of 88 patients receiving double CBT in CR1, delayed CR1 was related to high CIR, and age older than 40 years was associated with high NRM and early mortality. Unexpectedly, Ph-positive ALL with MRD had a higher NRM and early mortality than Ph-negative ALL and Ph-positive ALL without MRD subgroups, possibly due to delayed neutrophil and platelet recovery.

Conclusion: Our data suggest that double CBT for adult ALL in CR1 has a greater benefit in younger patients and in patients with Ph-positive ALL without MRD or Ph-negative ALL.

Keywords: acute lymphoblastic leukemia, double cord blood transplantation, early mortality, measurable residual disease, nonrelapse mortality

Received: 24 August 2021; revised manuscript accepted: 11 January 2022.
(HLA)-matched sibling donor (MSD) or matched unrelated donor (MUD) has been regarded as a primary post-remission treatment for adult ALL. However, a significant proportion of patients lack an HLA-matched donor, leaving the need for alternative HCT from mismatched unrelated donor (MMUD), haploidentical donor (HID), or umbilical cord blood (CB) sources. Because the impact of donor sources on transplantation outcomes remains uncertain and may vary according to underlying disease and pre-HCT disease status, we previously analyzed the impact of donor type (MSD versus MUD versus MMUD versus CB) on long-term HCT outcomes, particularly focusing on the donor-type-specific difference in graft-versus-host disease (GVHD)-free/relapse-free survival (GRFS) in a large cohort of adults with ALL in first CR (CR1). With respect to GRFS, we found the benefit of CBT for adult ALL in CR1, which in turn may lead to an improved long-term quality of life. Nevertheless, we must still consider delayed engraftment and early mortality of CBT due to lower cell counts compared to conventional donors. In addition, our previous interim data on double CBT showed that patients with Philadelphia chromosome (Ph)-positive ALL had worse survival outcome than patients with Ph-negative ALL, probably due to delayed engraftment and high nonrelapse mortality (NRM). Along with the subtype of ALL, the significance of immune-related parameters including HLA disparity, natural killer-cell alloreactivity, donor-specific antibodies (DSA), and noninherited maternal antigen (NIMA), and several clinical factors such as age and infused CD34+ cell count were also analyzed in several studies. However, most parameters have not been proven to be influencing factors and some unclarities should be discussed.

In this study, we aimed to analyze risk factors affecting mortality and survival outcomes of double CBT in a larger number of patients with a longer follow-up period.

**Patients and methods**

**Study population and treatment policy**

From March 2006 to December 2020, 112 consecutive adults with ALL who received double CBT at a single, the largest institution in Korea were enrolled in this study. We have treated ALL patients with a uniform frontline chemotherapy and offered allogeneic HCT according to donor availability as a post-remission treatment during first CR. In relapsed or refractory ALL, allogeneic HCT was performed as soon as possible if CR was obtained after salvage therapy. We previously reported HCT outcomes according to donor type in adults with ALL in CR1, including our donor hierarchy. Briefly, if an MSD is available, HCT is offered as a main post-remission therapy, irrespective of risk assessment. Patients who have no available MSD, especially those with high-risk features, are offered to receive MUD or 1-allele-MMUD transplantations. For patients without a suitable unrelated donor, CB was finally selected based on our center’s criteria. In the current study, CBT was performed in 88 patients during their CR1, 20 were in second CR (CR2, 9 of them were second transplantation), and the rest 4 were in non-CR (NR, 1 of them was second transplantation). First, we analyzed double CBT outcomes according to disease status in all patients. Then, we focused on patients treated with double CBT during CR1 for a detailed evaluation of risk factors. All patients provided written informed consent approved by the institutional review board of the Catholic University of Korea (KC17RESI0155). This study was conducted in accordance with the Declaration of Helsinki. The reporting of this study conforms to the STROBE statement (https://www.equator-network.org/).

**Pre-HCT chemotherapy**

As previously described, we applied modified hyper-CVAD, which consisted of cyclophosphamide, vincristine, daunorubicin, and dexamethasone (at each odd cycle). Then, patients received subsequent chemotherapy courses consisting of high-dose cytarabine and mitoxantrone (at each even cycle). Patients received up to four cycles in total, which was dependent on donor availability. In patients with Ph-positive ALL, tyrosine kinase inhibitors (imatinib or dasatinib) were added to the above chemotherapy regimens. Central nervous system prophylaxis was performed by intrathecal administration of triple agents (methotrexate, cytarabine, and hydrocortisone; six times in total). We defined patients who failed the first cycle of modified hyper-CVAD as primary refractory. For relapsed or primary refractory patients,
the MEC regimen consisting of high-dose cytarabine, mitoxantrone, and etoposide has been used, and since 2016, blinatumomab has also been used. If a patient achieved CR after salvage therapies mentioned above, we defined it as delayed CR1.

**Transplantation procedures**

We routinely used double CBs for all patients because no single CB unit was adequate for the cell dose during the study period. For the selection of CB units, minimum HLA typing requirements followed the current practice of low-resolution typing for HLA-A and -B and high-resolution typing of HLA-DRB1 (class I at antigen level and class II at allele level). When several units were available, a 6/6 HLA-matched unit was preferred to a 5/6 HLA-matched and a 5/6 unit to a 4/6. At the same overall HLA compatibility level, the units with the higher total nucleated cell (TNC) and CD34+ cell counts were selected. HLA disparities between each unit and the recipient and between the two units were not necessarily at the same loci. Overall, we tried to match at a minimum of 4/6 loci and checked the TNC and CD34+ cell counts at least \( \geq 3 \times 10^7 \) TNC/kg and \( \geq 1 \times 10^5 \) CD34+/kg. We did not routinely check donor-specific anti-HLA antibody or NIMA status. Conditioning regimen for double CBT consisted of TBI (12.0 Gy), fludarabine (150 mg/m^2), and cytarabine (9.0 g/m^2).\(^{13,15}\) Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis. The granulocyte-colony-stimulating factor was administered to all patients at a dose of 5 μg/kg/day subcutaneously from day 7 after transplantation until neutrophil recovery. Chimerism status was evaluated by short tandem repeat (STR) multiplex polymerase chain reaction (PCR) using an AmpFISTR Identifier PCR Amplification kit (Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. GeneMapper ID Software Version 4.1 (Applied Biosystems, Foster City, CA) was used for automated genotyping and quantification of peak areas. Samples were collected at 1 and 3 months post-CBT, and complete donor chimerism was defined as the detection of >95% of donor cells (from one or both CB units). For cytomegalovirus (CMV) reactivation surveillance, we monitored real-time quantitative (RQ)-PCR for CMV DNA after neutrophil engraftment. If the CMV RQ-PCR level was higher than 1000 copies/ml (equal to >6500 IU/ml), preemptive therapy was conducted to prevent CMV disease.\(^{30,31}\) If residual leukemia was detected in the absence of GVHD at 3 months after double CBT, immunosuppressive agents were rapidly discontinued. For Ph-positive ALL, minimal residual disease (MRD) monitoring for the \( BCR-ABL1 \) transcript was evaluated centrally by RQ-PCR (4.5-log sensitivity) using bone marrow samples, as previously described.\(^{26-28}\) Based on MRD response to tyrosine kinase inhibitors before double CBT, imatinib (400 mg daily) or dasatinib (100 mg daily) were administered preemptively for 2 years to patients with detectable MRD after double CBT. Since we performed MRD testing for Ph-negative ALL from late 2020, these results were not included in this study.

**Statistical analysis**

The primary endpoints of this study included overall survival (OS), DFS, NRM, cumulative incidence of relapse (CIR), GRFS, and cumulative incidence of GVHD and CMV reactivation. Survival curves were plotted using the Kaplan–Meier method, and subgroups were compared by log-rank tests. Relapse, NRM, and GVHD were calculated using cumulative incidence estimates to accommodate the following competing events (death for relapse, relapse for NRM, and both death and relapse for GVHD), and subgroups were compared by Gray test. The prognostic significance of covariates affecting OS and DFS was determined by Cox proportional hazards regression model. The prognostic significance of covariates affecting cumulative incidences of relapse, NRM, and GVHD was determined using Fine-Gray proportional hazards regression for competing events. Multivariate analyses were performed using variables with a \( p \) value <0.10 in preliminary univariate analyses. All statistical analyses were performed using ‘R’ software version 4.0.3 (R Foundation for Statistical Computing, 2020). Statistical significance was set at \( p \) value <0.05.

**Result**

**Patient characteristics**

Baseline characteristics at the time of diagnosis and double CBT for all 112 patients (105 B-cell ALL and 7 T-cell ALL) are summarized in Table 1. The median patient age was 35 years (range: 18–62 years). Poor-risk karyotype was identified in

---

\( p \) value
|                                | Total patients [n = 112] | CBT in CR1 [n = 88] | CBT in ⩾ CR2 [n = 24] | p         |
|--------------------------------|--------------------------|---------------------|-----------------------|-----------|
| Age, median (range), years     | 35 (18–62)               | 35 (18–62)          | 33 (18–57)            | 0.801     |
| <40, n [%]                     | 71 (63.4)                | 56 (63.6)           | 15 (62.5)             | 1.000     |
| ⩾40, n [%]                     | 41 (36.6)                | 32 (36.4)           | 9 (37.5)              |           |
| Male gender, n [%]             | 54 (48.2)                | 40 (45.5)           | 14 (58.3)             | 0.357     |
| Leukocyte count, median (range), ×10⁹/L | 16.9 (1.1–691.0)     | 21.2 (1.1–691.0)   | 11.8 [2.2–374.9]     | 0.635     |
| ⩾30×10⁹/L, n [%]               | 42 (37.5)                | 33 (37.5)           | 9 (37.5)              | 1.000     |
| B-cell subtype, n [%]          | 105 (93.7)               | 83 (94.3)           | 22 (91.7)             | 0.641     |
| T-cell subtype, n [%]          | 7 (6.3)                  | 5 (5.7)             | 2 (8.3)               | 0.641     |
| Karyotype, n [%]               |                          |                     |                      | 0.818     |
| Standard-risk                  | 51 (45.5)                | 41 (46.6)           | 10 (41.7)             |           |
| Poor-risk                      | 61 (54.5)                | 47 (53.4)           | 14 (58.3)             |           |
| Ph                             | 50 (44.6)                | 39 (44.3)           | 11 (45.8)             |           |
| KMT2A rearrangement            | 5 (4.5)                  | 4 (4.5)             | 1 (4.2)               |           |
| Complex karyotype              | 4 (3.6)                  | 2 (2.3)             | 2 (8.3)               |           |
| Extramedullary involvement, n [%] | 53 (47.3)              | 38 (43.2)           | 15 (62.5)             | 0.110     |
| CR achievement                 |                          |                     |                      | 0.106     |
| CR after induction chemotherapy, n [%] | 96 (85.7)            | 78 (88.6)           | 18 (75.0)             |           |
| Delayed CR, n [%]              | 16 (14.3)                | 10 (11.4)           | 6 (25.0)              |           |
| Previous HCT history, n [%]    | 10 (8.9)                 | 0 (0.0)             | 10 (41.7)             | <0.001    |
| Ph-subgroup and pre-CBT MRD, n [%] | 62 (55.4)              | 49 (55.7)           | 13 (54.2)             | 0.861     |
| Ph-negative ALL                |                          |                     |                      |           |
| Ph-positive ALL without MRD    | 27 (24.1)                | 22 (25.0)           | 5 (20.8)              |           |
| Ph-positive ALL with MRD       | 23 (20.5)                | 17 (19.3)           | 6 (25.0)              |           |
| Year of CBT, n [%]             |                          |                     |                      |           |
| 2006–2013                      | 27 (24.1)                | 22 (25.0)           | 5 (20.8)              | 0.792     |
| 2014–2020                      | 85 (75.9)                | 66 (75.0)           | 19 (79.2)             |           |
| Sex match, n [%]               |                          |                     |                      | 0.466     |
| Female to male                 | 38 (33.9)                | 28 (31.8)           | 10 (41.7)             |           |
| Others                         | 74 (66.1)                | 60 (68.2)           | 14 (58.3)             |           |
| ABO match, n [%]               |                          |                     |                      | 0.078     |

(Continued)
Table 1. (Continued)

|                        | Total patients (n = 112) | CBT in CR1 (n = 88) | CBT in ≥ CR2 (n = 24) | p     |
|------------------------|--------------------------|---------------------|-----------------------|-------|
| Match                  | 6 (5.4)                  | 3 (3.4)             | 3 (12.5)              |       |
| Minor mismatch         | 23 (20.5)                | 16 (18.2)           | 7 (29.2)              |       |
| Major mismatch         | 83 (74.1)                | 69 (78.4)           | 14 (58.3)             |       |
| TNC, median (×10⁷/kg)  | 4.04 (1.58–7.88)         | 3.98 (1.58–7.88)    | 4.15 (2.72–7.60)      | 0.375 |
| ≥3.0×10⁷/kg, n (%)     | 94 (80.6)                | 74 (82.4)           | 20 (78.8)             | 1.000 |
| CD34+ cells, median (×10⁵/kg) | 1.09 [0.33–5.85] | 1.08 [0.33–5.85]    | 1.15 [0.49–4.84]      | 0.457 |
| ≥1.0×10⁵/kg, n (%)     | 64 (64.2)                | 48 (52.9)           | 16 (75.8)             | 0.355 |
| CD3+ cells, median (×10⁶/kg) | 5.66 [1.50–14.2]    | 5.42 [1.50–13.05]   | 5.95 [2.99–14.2]      | 0.055 |
| Median time to CBT, months (range) | 6.8 (3.5–92.2) | 6.5 (3.5–10.4)      | 13.5 (6.2–92.2)       | <0.001 |

ALL, acute lymphoblastic leukemia; CBT, cord blood transplantation; CR, complete remission; HCT, hematopoietic cell transplantation; MRD, measurable residual disease; Ph, Philadelphia chromosome; TNC, total nucleated cells.

61 patients (54.5%), and among them, Ph was observed in 50 patients (44.6%). Double CBT was performed in 88 patients during CR1, while 24 were in ≥ CR2 [4 of them were in NR (3 Ph-positive ALL and 1 Ph-negative ALL)] who had a longer time interval from diagnosis to transplantation (6.5 versus 13.5 months, p < 0.001) and 10 were second transplantation. Median TNC count was 4.04 × 10⁷ cells/kg, and 94 patients (80.6%) received ≥3.0 × 10⁷ TNC/kg (range: 0.33–5.85 × 10⁷ TNC/kg). Median CD34+ cell count was 1.09 × 10⁵ cells/kg, and 64 (64.2%) patients received ≥1 × 10⁵ cells/kg (range: 1.58–7.88 × 10⁵ cells/kg).

Engraftment, GVHD, and CMV reactivation

The cumulative incidence of neutrophil and platelet engraftment was 95.5% and 88.9%, and the median time for neutrophil and platelet recovery was 25 days (range: 5–59 days) and 34 days (range: 7–185 days), respectively. We observed that platelet count recovery was delayed in Ph-positive ALL compared to Ph-negative ALL (40 days versus 32 days, p = 0.055), while the neutrophil recovery was not different (26 days versus 25 days, p = 0.460). The chimerism status was evaluated in 99 (88.4%) patients at 1 month and in 92 (82.1%) at 3 months, respectively. Among them, complete donor chimerism was detected in 92.9% (92/99) at 1 month and 97.8% (90/92) of patients at 3 months, respectively. All patients with complete donor chimerism had a single unit predominance of >70% of donor cells. Except for 7 patients who died during aplasia, 49 developed acute GVHD (39 grade II, 7 grade III, and 3 grade IV), and the cumulative incidence of acute GVHD at 100-day was 41.1% and at 1 year was 43.8%. The cumulative incidence of acute GVHD with grades III–IV was 8.9% (Figure 1(a)). Except for patients who died within 100 days without chronic GVHD, 23 developed chronic GVHD (14 mild, 8 moderate, 1 severe), resulting in a 5-year cumulative incidence of 22.0%, and moderate to severe chronic GVHD was observed in 8.5% (Figure 1(b)). We experienced CMV reactivation in 91 (81.3%) patients, and 65 (71.4%) of them with high level of reactivation received preemptive antiviral therapy. The cumulative incidence of treated CMV reactivation was 58.4% (Figure 1(c)). However, there was no significant difference in OS according to CMV reactivation (54.7% versus 70.8%, p = 0.494; data not shown). Overall, 18 (16.1%) patients died within 100-day post-CBT – 11 were due to sepsis, 4 due to GVHD, 2 due to organ failure, and 1 due to brain hemorrhage (Figure 1(d)).
Survival outcomes of the entire cohort
Of a total of 112 patients, 17 relapsed at a median of 5.9 months (range: 0.1–20.5 months) after transplantation. The 5-year CIR was 12.7% (9.7% for patients in CR1% and 25.7% in CR2; p < 0.001; Figure 2(a)). Totally, 31 patients died of NRM at a median of 3.2 months (range: 0.3–26.6 months) after transplantation. The 5-year incidence of NRM was 28.5% [27.2% for patients in CR1, 40.0% in CR2, and 0.0% in NR (all died of leukemia); p = 0.218; Figure 2(b)]. After a median follow-up duration of 60.1 months (range: 5.7–181.3), 66 of the 112 patients remained alive. At the time of analysis, 46 patients had died (15 disease progression, 31 NRM). The primary causes of death were infections (n = 16), relapse (n = 15), GVHD (n = 10), organ failure (n = 4), and hemorrhage (n = 1). Five-year DFS and OS were 57.6% (63.1% for patients in CR1 and 34.3% in CR2) and 57.9% (66.5% for patients in CR1, 33.0% in CR2, and 0.0% in NR), respectively (Figure 2(c) and (d)). Five-year GRFS was 49.6% (55.5% for patients in CR1 and 24.0% in CR2; Figure 2(e)).

Survival outcomes in CR1 subgroup
As the entire patient cohort comprised variable imbalances in disease status, previous allogeneic HCT history, and time to transplantation, we focused on patients receiving double CBT in CR1 to analyze adverse prognostic factors. In this

---

**Figure 1.** Transplantation complications and early death after double CBT. (a) Cumulative incidence of acute GVHD. (b) Cumulative incidence of chronic GVHD. (c) CMV reactivation. (d) Cumulative incidence of early death within 100 days. *Aplasia deaths without acute GVHD and early deaths or relapse within 100 days without chronic GVHD were treated as competing risks.*
subgroup of patients, OS (56.9% versus 74.0%) and NRM (34.8% versus 21.4%) were not significantly different between Ph-positive ALL and Ph-negative ALL (Figure 3(a) and (b)) and CIR (10.5% for Ph-positive ALL versus 9.0% for Ph-negative ALL, \( p = 0.718 \)) was also similar. However, when we further analyzed considering both Ph-positivity and pre-HCT MRD status,
Ph-positive ALL with MRD subgroup (n = 17) showed the worst OS and DFS (39.7% and 40.3%) compared to Ph-positive ALL without MRD (n = 22; 70.1% and 65.6%, p = 0.071 and p = 0.181, respectively) and Ph-negative ALL (n = 49; 74.0% and 69.6%, p = 0.010 and p = 0.017, respectively) subgroups (Figure 3(c) and (d)). In Figure 3(e) and (f), we identified that poor survival outcome was due to higher NRM of Ph-positive ALL with MRD subgroup compared to other subgroups (47.8% versus 24.8% and 21.4%, p = 0.047) rather than CIR (11.8% versus 9.4% versus 9.0%, p = 0.916). We identified early death rate within 100 days post-CBT was significantly higher in Ph-positive ALL with MRD subgroup than other subgroups (35.3% versus 9.1% versus 4.1%, p = 0.001). In multivariate analysis (Table 2), the early death rate was significantly higher in patients older than 40 years (HR = 22.6, 95% CI; 2.8–178.2, p = 0.003) and Ph-positive ALL with MRD subgroup (HR = 13.6, 95% CI; 2.9–64.3, p < 0.001), and the overall NRM was also higher in patients older than 40 years (HR = 6.72, 95% CI; 2.6–17.0, p < 0.001) and Ph-positive ALL with MRD subgroup (HR = 4.69, 95% CI; 1.9–11.2, p < 0.001). Delayed CR1 was the most adverse risk factor affecting CIR (HR = 9.59, 95% CI; 2.5–35.9, p < 0.001). For survival outcomes, all factors discussed above (old age, delayed CR, and Ph-positive ALL with MRD subgroup) were significant for both OS and DFS. Age older than 40 years (HR = 1.89, 95% CI; 1.1–3.2, p = 0.016) was associated with a poorer GRFS.

Discussion

CB is a readily available donor source for patients who do not have a suitable conventional donor, but we still have to consider a delayed engraftment and early fatality.13,14 We have been using double CBs as a primary alternative donor source for over a decade, and as our experience with its pros and cons has accumulated, we clearly felt the need to identify better CBT candidates. Our previous interim data on double CBT showed that patients with Ph-positive ALL had a poorer DFS than patients with Ph-negative ALL (37.7% versus 66.5%, p = 0.017), with trends of higher CIR and NRM.15 However, in this study with a larger number of patients and more extended follow-up, Ph-positive ALL still showed poorer outcomes than Ph-negative ALL, but the difference was not statistically significant. However, when we further analyzed considering both Ph-positivity and MRD status before CBT, Ph-positive ALL with MRD subgroup showed significantly worse survival outcomes due to significantly higher NRM than Ph-negative ALL or Ph-positive ALL without MRD subgroups. In this Ph-positive ALL with MRD subgroup, the early death rate within 100 days post-CBT was exceptionally high, accounting for 75.0% of all NRM cases, resulting in a poorer OS than other subgroups. Overall, irrespective of disease subgroup, age older than 40 years was an important factor in high NRM and early mortality.

For both Ph-positive and Ph-negative ALL, MRD has been proven as one of the most important factors for predicting survival outcome after allogeneic HCT.27–29,32–34 Pre-transplantation positive MRD is generally supposed to be related to subsequent relapse rather than NRM.35,36 However, our data showed that NRM, especially early mortality, were significantly higher in Ph-positive ALL with MRD subgroup after double CBT. As a result, the long-term CIR was not substantially higher than Ph-positive ALL without MRD or Ph-negative ALL subgroups. These were unexpected findings and might be a coincidence. However, as a possible reason for frequent early deaths in Ph-positive ALL with MRD subgroup, we suggest that delayed neutrophil (29 days versus 24 days, p = 0.038) and platelet (42 days versus 37 days, p = 0.056) recovery may increase fatal infectious or hemorrhagic complications, possibly due to myeloablative conditioning regimen (Supplementary Table 1). A recent study found a higher incidence of bloodstream infection after CBT, which was more severe in patients with delayed neutrophil engraftment, TBI conditioning, and infection with multidrug resistance. They also showed that NR or advanced disease status before CBT was at high-risk of bloodstream infection (37.9% versus 24.1%), although it was offset in the multivariate analysis.37

Vice versa, many early deaths may offset possible candidates for subsequent relapse, resulting in a similar overall CIR between Ph-positive ALL with MRD subgroup and other subgroups in our study. Recently, Milano et al. examined the effect of MRD on mortality and relapse between the donor sources (CB versus MUD versus MMUD).38 The authors showed that the risk of relapse was
significantly lower in the CBT group than in either MUD or MMUD groups, while no significant difference in NRM was found between the three groups. Interestingly, pre-HCT MRD status had a significant impact on risks of death and relapse among patients receiving MUD- or
Table 2. Uni- and multivariate analyses in adult ALL patients treated with double CBT in CR1.

| Variables                      | Early death | NRM | CIR | GRFS |
|-------------------------------|-------------|-----|-----|------|
|                               | Univariate  | Multivariate | Univariate  | Multivariate | Univariate  | Multivariate | Univariate  | Multivariate |
|                               | 100-day     | p    | 5-year NRM | p    | 5-year CIR | p    | 5-year GRFS | p |
|                               | mortality   | HR (95% CI) | p    | HR (95% CI) | p    | HR (95% CI) | p    | HR (95% CI) | p |
| Age at diagnosis              |             |       |       |       |       |       |       |       |       |
| <40 years [n = 56]            | 1.8%        | <0.001| 13.6% | <0.001| 9.8%   | 0.964| 68.4% | 0.001| 1 |
| ≥40 years [n = 32]            | 12.5%       | 22.6 (2.8–178.2) | 0.003| 50.0% | 13.6% | 6.72 (2.6–17.0) | <0.001| 9.4% |
| Initial leukocyte count        |             |       |       |       |       |       |       |       |       |
| <30 x 10^9/L [n = 55]         | 3.6%        | 0.371| 19.1% | 0.037| 7.6%   | 0.498| 66.8% | 0.025| 33.6% |
| ≥30 x 10^9/L [n = 33]         | 9.1%        | 40.2%| 13.0% |       |       |       |       |       |       |
| CR achievement                |             |       |       |       |       |       |       |       |       |
| CR after induction [n = 78]   | 3.8%        | <0.001| 26.6% | 0.692| 5.2%   | <0.001| 1     | 59.7% | 0.094 |
| Delayed CR [n = 10]           | 20.0%       | 31.4%|       |       |       |       |       |       | 23.3% |
| Ph-subgroup and MRD           |             |       |       |       |       |       |       |       |       |
| Ph-negative ALL [n = 49]      | 2.0%        | 0.002| 21.4% | 0.047| 9.0%   | 0.916| 59.7% | 0.056| 33.6% |
| Ph-positive ALL, MRD-negative [n = 22] | 0.0% | 1.91 (0.29–12.7) | 0.500| 24.8% | 0.97 (0.3–2.9) | 0.970| 9.4% | 63.0% |
| Ph-positive ALL, MRD-positive [n = 17] | 23.5% | 13.6 (2.9–64.3) | <0.001| 47.8% | 4.69 (1.9–11.2) | <0.001| 11.8% | 34.3% |
| Karyotype                     |             |       |       |       |       |       |       |       |       |
| Standard-risk [n = 41]        | 2.4%        | 0.014| 20.8% | 0.152| 8.2%   | 0.561| 59.1% | 0.344| 54.5% |
| Poor-risk [n = 47]            | 19.1%       | 33.1%|       |       |       |       |       |       |       |
| Extramedullary involvement    |             |       |       |       |       |       |       |       |       |
| No [n = 50]                   | 5.0%        | 0.809| 25.2% | 0.630| 10.5% | 0.720| 62.8% | 0.138| 21.5% |

(Continued)
| Variables                  | Early death | NRM          | CIR           | GRFS          |
|----------------------------|-------------|--------------|---------------|---------------|
|                            | Univariate  | Multivariate | Univariate    | Multivariate  | Univariate    | Multivariate  |
|                            | 100-day     | 5-year NRM   | 5-year CIR    | 5-year GRFS   | p             | HR (95% CI)   |
| Early death                | p           | p            | p             | p             |               |               |
| Yes [n = 38]               | 5.3%        | 30.0%        | 8.4%          | 46.2%         |               |               |
| Year of CBT                |             |              |               |               |               |               |
| 2006–2013 [n = 22]         | 9.1%        | 0.743        | 31.8%         | 9.1%          | 0.913         | 40.9%         | 0.104         |
| 2014–2020 [n = 66]         | 12.1%       | 25.0%        | 9.7%          | 61.0%         |               |               |
| CD34+ cells                |             |              |               |               |               |               |
| $\geq1.0 \times 10^5 / kg$ | 2.5%        | 0.086        | 19.0%         | 14.1%         | 0.282         | 65.6%         | 0.055         |
| [n = 40]                   |             |              |               |               |               |               |
| $<1.0 \times 10^5 / kg$    | 8.3%        | 0.097        | 6.2%          | 47.2%         |               |               |
| [n = 48]                   |             |              |               |               |               |               |
| CMV reactivation           |             |              |               |               |               |               |
| No [n = 16]                | 12.5%       | 0.819        | 12.5%         | 20.2%         | 0.152         | 48.1%         | 0.430         |
| Yes [n = 72]               | 11.1%       | 30.5%        | 7.3%          | 57.3%         |               |               |

ALL, acute lymphoblastic leukemia; CBT, cord blood transplantation; CI, confidence interval; CIR, cumulative incidence of relapse; CMV, cytomegalovirus; CR, complete remission; GRFS, graft-versus-host disease-free/relapse-free survival; MRD, measurable residual disease; NRM, nonrelapse mortality; Ph, Philadelphia chromosome.
MMUD-HCT but no impact among patients receiving CBT. These important results should be confirmed in future studies. Moreover, we need solutions to reduce early mortality in high-risk patients, such as older patients or those with MRD/advanced disease status, by modulating conditioning intensity or using other alternative donors such as HID.

CBT has a high-risk for CMV reactivation due to slow CMV-specific immune reconstitution. CMV seropositivity is frequent in the Korean population, and post-CBT CMV reactivation is confirmed in many patients. Our data showed that CMV reactivation was observed in 81.3% and about 70% of them were treated with antiviral agents. Because antiviral agents suppress BM function, active preemptive treatment of CMV in the early post-CBT period may be harmful to hematological stability after CBT. Nevertheless, survival outcomes were not significantly different according to CMV reactivation.

Several studies have reported that single CBT showed more frequent engraftment failure, while double CBT showed more frequent acute GVHD or extensive chronic GVHD. Along with the high incidence of GVHD, an enhanced GVL effect was also observed after double CBT, and one study found a significantly lower incidence of relapse with TBI-based conditioning regimen without antithymocyte globulin. In this study, all patients were treated with double CBT after TBI-based myeloablative conditioning without antithymocyte globulin. Our data showed that the cumulative incidence of grade III-IV acute GVHD and moderate to severe chronic GVHD was less than 10% each, indicating a relatively lower incidence of clinically significant GVHD compared to other studies. In addition, most acute or chronic GVHD could be managed safely, and only a small number of GVHD-related deaths occurred. The reasons for the low incidence of grade III-IV acute GVHD in this study are not clear, but it is likely due to the relatively lower number of infused cells compared to other studies. Indeed, despite the use of double CBs for all patients in this study, the median number of TNC was $4.04 \times 10^7$/kg, $1.09 \times 10^5$/kg for CD34+ cells, and $5.66 \times 10^6$/kg for CD3+ cells, which were lower than those in other reports. Another possible cause is that the high early mortality within 100 days post-CBT may have partially masked the true incidence of acute GVHD.

Several comparative studies showed no significant difference in survival outcome between single CBT and double CBT if a single unit had sufficient cell dose and HLA compatibility. Although our previous interim data showed that a lower CD34+ cell number was associated with a higher NRM after double CBT, it was not significant in this final analysis. This might be due to our appropriate CB selection criteria. However, we could not compare the results of double CBT with single CBT as no single CB unit met the minimum cell dose criteria during the study period in Korea.

In summary, our data suggest that double CBT for adult ALL in CR1 has a greater benefit in younger patients and in patients with Ph-positive ALL without MRD or Ph-negative ALL. However, delayed engraftment and high risk of early mortality are important issues to be addressed. In addition, our data opened a discussion point for Ph-positive ALL with MRD subgroup at high risk of overall NRM and early mortality. Our study has the limitation that it cannot fully address the effect of MRD status on CBT outcomes because MRD data were analyzed only for Ph-positive ALL. To address the importance of MRD status for both NRM and relapse in the CBT setting for adult ALL, our results should be further evaluated with thorough MRD monitoring.

Author contributions
Jae-Ho Yoon: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Writing – original draft; Writing – review & editing.
Gi June Min: Investigation; Methodology; Resources.
Sung-Soo Park: Investigation; Methodology; Resources.
Silvia Park: Investigation; Methodology; Resources.
Sung-Eun Lee: Investigation; Methodology; Resources.
Byung-Sik Cho: Investigation; Methodology.
Ki-Seong Eom: Investigation; Methodology.
Yoo-Jin Kim: Investigation; Methodology.
Hee-Je Kim: Investigation; Methodology.
Chang-Ki Min: Supervision.
Seok-Goo Cho: Supervision.
Jong Wook Lee: Supervision.
Seok Lee: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Resources; Supervision; Validation; Writing – original draft; Writing – review & editing.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Ethics, consent, and permissions
All patients were provided written informed consent. This research was permitted and conducted following the Institutional Review Board and Ethics Committee guidelines of the Catholic Medical Center (KC17RESI0155).

Consent for publication
Written informed consent was obtained at the stage of diagnosis in all patients. This manuscript does not contain any individual’s personal data.

ORCID iDs
Jae-Ho Yoon https://orcid.org/0000-0002-2145-9131
Sung-Eun Lee https://orcid.org/0000-0002-9810-2050
Yoo-Jin Kim https://orcid.org/0000-0001-6653-2956
Jong Wook Lee https://orcid.org/0000-0003-2949-4166

Availability of data and materials
All data generated or analyzed during this study are included in this published article. Datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Supplemental material
Supplemental material for this article is available online.

References
1. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. *J Clin Oncol* 2004; 22: 4075–4086.
2. Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. *Cancer* 2004; 101: 2788–2801.
3. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. *Blood* 2005; 106: 3760–3767.
4. Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. *Cancer* 2006; 106: 2657–2663.
5. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood* 2008; 111: 1827–1833.
6. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. *J Clin Oncol* 2004; 22: 2816–2825.
7. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. *N Engl J Med* 2014; 371: 339–348.
8. Marks DI, Perez WS, He W, et al. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. *Blood* 2008; 112: 426–434.
9. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant 2008; 41: 473–481.

10. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008; 112: 3574–3581.

11. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265–2275.

12. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276–2285.

13. Yoon JH, Min GJ, Park SS, et al. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2021; 56: 828–840.

14. Nishiwaki S, Miyamura K, Ohashi K, et al. Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Ann Oncol 2013; 24: 1594–1602.

15. Yoon JH, Park SS, Jeon YW, et al. Durable outcomes of a prospective double cord blood transplantation trial in adults with acute lymphoblastic leukemia: different outcomes according to the presence of Philadelphia chromosome. Blood 2017; 130(Suppl. 1): 2550.

16. Stevens CE, Carrier C, Carpenter C, et al. HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection. Blood 2011; 118: 3969–3978.

17. Kanda J, Ichinohe T, Fuji S, et al. Impact of HLA mismatch direction on the outcome of unrelated bone marrow transplantation: a retrospective analysis from the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2015; 21: 305–311.

18. Cunha R, Loiseau P, Ruggeri A, et al. Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. Bone Marrow Transplant 2014; 49: 24–29.

19. Leung W. Use of NK cell activity in cure by transplant. Br J Haematol 2011; 155: 14–29.

20. Tanaka J, Morishima Y, Takahashi Y, et al. Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer J 2013; 3: e164.

21. Takanashi M, Atsuta Y, Fujiwara K, et al. The impact of anti-HLA antibodies on unrelated cord blood transplantations. Blood 2010; 116: 2839–2846.

22. Cutler C, Kim HT, Sun L, et al. Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood 2011; 118: 6691–6697.

23. Rocha V, Spellman S, Zhang MJ, et al. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2012; 18: 1890–1896.

24. Matsumura T, Kami M, Yamaguchi T, et al. Allogeneic cord blood transplantation for adult acute lymphoblastic leukemia: retrospective survey involving 256 patients in Japan. Leukemia 2012; 26: 1482–1486.

25. Barker JN, Fei M, Karanes C, et al. Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia. Br J Haematol 2015; 168: 405–412.

26. Eom KS, Shin SH, Yoon JH, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol 2013; 88: 634–641.

27. Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2012; 26: 2367–2374.

28. Yoon JH, Min GJ, Park SS, et al. Minimal residual disease-based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer 2019; 125: 873–883.
29. Yoon JH, Yhim HY, Kwak JY, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. *Ann Oncol* 2016; 27: 1081–1088.

30. Choi SM, Lee DG, Choi JH, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. *Int J Hematol* 2005; 81: 69–74.

31. Choi SM, Lee DG, Lim J, et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. *J Korean Med Sci* 2009; 24: 571–578.

32. Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. *JAMA Oncol* 2017; 3: e170580.

33. Van Dongen JJ, Van Der Velden VH, Bruggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. *Blood* 2015; 125: 3996–4009.

34. Bourlon C, Lacayo-Lenero D, Inclan-Alarcon SI, et al. Hematopoietic stem cell transplantation for adult Philadelphia-negative acute lymphoblastic leukemia in the first complete remission in the era of minimal residual disease. *Curr Oncol Rep* 2018; 20: 36.

35. Tanaka Y, Kurosawa S, Tajima K, et al. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2016; 51: 553–559.

36. Pavlu J, Labopin M, Nittuyuopio R, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. *J Hematol Oncol* 2019; 12: 108.

37. Ge J, Yang T, Zhang L, et al. The incidence, risk factors and outcomes of early bloodstream infection in patients with malignant hematologic disease after unrelated cord blood transplantation: a retrospective study. *BMC Infect Dis* 2018; 18: 654.

38. Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. *N Engl J Med* 2016; 375: 944–953.

39. Bejanyan N, Vlasova-St Louis I, Mohei H, et al. Cytomegalovirus-specific immunity recovers more slowly after cord blood transplantation compared with matched sibling donor allogeneic transplantation. *Transplant Cell Ther* 2021; 27: 187.e1–187.e4.

40. Yoon JH, Lee S, Kim HJ, et al. Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission. *Oncotarget* 2016; 7: 17230–17241.

41. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. *Lancet Oncol* 2010; 11: 653–660.

42. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. *Blood* 2011; 118: 282–288.

43. Chen YB, Wang T, Hemmer MT, et al. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. *Bone Marrow Transplant* 2017; 52: 400–408.

44. Sideri A, Neokleous N, Brunet De La Grange P, et al. An overview of the progress on double umbilical cord blood transplantation. *Haematologica* 2011; 96: 1213–1220.

45. Michel G, Galambrun C, Sirvent A, et al. Single-vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome. *Blood* 2016; 127: 3450–3457.

46. Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. *Blood* 2009; 114: 4293–4299.

47. Wagner JE Jr, Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. *N Engl J Med* 2014; 371: 1685–1694.